Last reviewed 2026-05-24 · How we verify

Bemeticide (BEMETIZIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Bemeticide (generic name: BEMETIZIDE) is a bemetizide drug. It is currently in Phase 2 development.

Bemetizide is thought to work by modulating ion transport across cell membranes.

Bemeticide is a small molecule with synonyms including BEMETIZIDA, BEMETIZIDE, and DEHYDROSANOL. Its modality is classified as a small molecule.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BEMETIZIDE
Drug class	bemetizide
Modality	Small molecule
Therapeutic area	Nephrology
Phase	Phase 2

Mechanism of action

Imagine your cells have special channels that let certain substances in and out. Bemetizide is a small molecule that can fit into these channels and change how they work, which can affect the balance of substances inside and outside the cell.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bemeticide CI brief — competitive landscape report
Bemeticide updates RSS · CI watch RSS

Frequently asked questions about Bemeticide

What is Bemeticide?

Bemeticide (BEMETIZIDE) is a bemetizide drug.

How does Bemeticide work?

Bemetizide is thought to work by modulating ion transport across cell membranes.

What is the generic name of Bemeticide?

BEMETIZIDE is the generic (nonproprietary) name of Bemeticide.

What drug class is Bemeticide in?

Bemeticide belongs to the bemetizide class. See all bemetizide drugs at /class/bemetizide.

What development phase is Bemeticide in?

Bemeticide is in Phase 2.

Drug class: All bemetizide drugs
Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing